Figure 1.

Impact of aneuploidy on cancer drug development (a): Tumor karyotyping could be used to identify highly aneuploid tumors and stratify patients for aneuploidy-targeting treatments. (b): Ongoing spindle assembly checkpoint (SAC) inhibition clinical trials target the SAC regulator monopolar spindle 1 (MPS1); we found aneuploid cells to be particularly sensitive to budding uninhibited by benzimidazoles 1 Beta (BUB1B), mitotic arrest deficient 2 like 1 (MAD2) and Kinesin family member 18A (KIF18A) knockdown, highlighting them as potential therapeutic targets. (c): Aneuploid cells were found to be more resistant to SAC inhibitors in short-term drug assays (3–5d), but more sensitive in longer assays (14d), emphasizing that prolonged exposure is critical for the full assessment of drug sensitivity. ~ 2 n, near-diploid cells; >> 2 n, highly aneuploid cells